News | September 12, 2025
VedaBio to use Mammoth Biosciences’ CRISPR-based technology for diagnostic applications
CRISPR-based detection enables highly specific molecular recognition
CRISPR-based detection enables highly specific molecular recognition
The period from 2020 to 2022 witnessed a remarkable surge in deal worth
Approximately 16,000 patients 12 years of age and older with severe sickle cell disease may now be eligible for this one-time treatment
CrisprBits has developed a platform to build rapid, precise, and affordable POC tests for a wide range of disease and health conditions
Agilent respectfully disagrees with the PTAB’s opinion of unpatentability in view of prior art previously considered by the USPTO during its primary examination
OmiCrisp has been developed with support from Centre for Cellular And Molecular Platforms C-CAMP-InDx Program
If authorized by the USFDA, the Proof Lab Test System may be used to deliver accurate, actionable, lab-quality results for Covid-19 in as little as 18 minutes
Growing CRISPR genome editing portfolio supports researchers on path to future therapeutic applications
Initiation of EBT-101 Phase 1/2 clinical trial expected later this year
Conventional plasmids as a pharmaceutical material are not only suboptimal in safety and function, but exceedingly costly to produce, prohibitively
Subscribe To Our Newsletter & Stay Updated
